Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Business

Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launch

Roche's Genentech has settled a US lawsuit against Indian biopharmaceutical company Biocon over its proposed biosimilar of Genentech's blockbuster breast-cancer drug Perjeta, Biocon said Wednesday.

* Biocon said in a statement that the settlement gives it the "earliest licensed launch dates" for a Perjeta biosimilar, allowing the company to launch its Pebrilzo in the first quarter of 2027 in the UK and European Union, and the third quarter of 2028 in the United States

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.